28 results
PRRN14A
ANIK
Anika Therapeutics Inc.
6 Apr 23
Revised preliminary proxy statement filed by non-management
5:24pm
underperformed the XBI by 17% annually and shareholders have lost 42% of their investment under her tenure on the Board.13 In Caligan’s conversations … has not shown appropriate accountability for the substantial value destruction that has occurred under her tenure.
Since Mr. Henneman joined
PRER14A
ANIK
Anika Therapeutics Inc.
5 Apr 23
Preliminary revised proxy
11:19am
.
Board Representation
DIVERSITY
INDEPENDENCE
TENURE
4 of our 7 continuing directors and director nominees voluntarily self-identify as having … and SEC regulations.
The tenure of our continuing directors and director nominees (average 5.2 years) reflects a balance between experience and fresh
PREC14A
i97wq67svmzs7pfcjl
30 Mar 23
Preliminary proxy with contested solicitation
5:12pm
DEFA14A
9b1m64xq
1 Jun 22
Additional proxy soliciting materials
12:08pm
DEFA14A
0xcs6cg fg4tovuy2iq
9 May 22
Additional proxy soliciting materials
4:00pm
8-K
EX-99.1
oqr55m7stsfcs7
8 Sep 20
Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
5:22pm
8-K
EX-10.1
n5euz
5 Aug 20
Anika Appoints Michael Levitz as Chief Financial Officer
5:04pm